Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis

Executive Summary

Pfizer's fourth-quarter call will be the first with new CEO Albert Bourla, while Amgen will provide reassurances after US Neulasta and Epogen biosimilar launches. Also, concerns swirl around the impending impact of generics on Allergan's blockbuster Restasis, Biogen investors await news on Alzheimer's programs and M&A, and Novartis will face scrutiny of recent launches.

You may also be interested in...



Biogen Q2 Preview: Can It Change The Narrative After Q1 Strength Was Overshadowed?

Despite 11% sales growth during the first quarter, Biogen faces pessimism about continuing to pursue the amyloid hypothesis in Alzheimer’s and competitive threats to Spinraza and Tecfidera. ALS and biosimilars may offer upside.

Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures

With Neulasta and Epogen facing competition and potential Sensipar generics launching this year, the company said revenues will fall from $23.7bn in 2018 to $21.8bn-$22.9bn in 2019. Amgen expects new launches and volume-driven sales growth – not price hikes – to boost revenue in the future.

Allergan Thinks It’s Ready To Withstand Restasis Generics

Allergan’s Restasis patent cliff is imminent: full-year sales of the dry eye product declined 14% and the firm expects US generic competition by Q2. But Botox growth is steady, Vraylar is poised to add a major indication and other pipeline assets may add growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel